303 related articles for article (PubMed ID: 28692839)
1. Rivaroxaban versus warfarin in the prevention of post-thrombotic syndrome.
Jeraj L; Jezovnik MK; Poredos P
Thromb Res; 2017 Sep; 157():46-48. PubMed ID: 28692839
[TBL] [Abstract][Full Text] [Related]
2. Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome.
Utne KK; Dahm A; Wik HS; Jelsness-Jørgensen LP; Sandset PM; Ghanima W
Thromb Res; 2018 Mar; 163():6-11. PubMed ID: 29324334
[TBL] [Abstract][Full Text] [Related]
3. Low prevalence of Post-thrombotic syndrome in patients treated with rivaroxaban.
Ferreira T; Huber SC; de Moraes Martinelli B; Junior AL; Menezes FH; Orsi FA; Bittar LF; de Oliveira LFG; Sodre LR; Mello TT; Rielli G; Colella MP; de Paula EV; Yamaguti-Hayakawa GG; Montalvão S; Annichino-Bizzacchi JM
Vascul Pharmacol; 2020 Jan; 124():106608. PubMed ID: 31678199
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of rivaroxaban in prevention of post-thrombotic syndrome: A systematic review and meta-analysis.
Karathanos C; Nana P; Spanos K; Kouvelos G; Brotis A; Matsagas M; Giannoukas A
J Vasc Surg Venous Lymphat Disord; 2021 Nov; 9(6):1568-1576.e1. PubMed ID: 33965611
[TBL] [Abstract][Full Text] [Related]
5. Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis.
Cheung YW; Middeldorp S; Prins MH; Pap AF; Lensing AW; Ten Cate-Hoek AJ; Villalta S; Milan M; Beyer-Westendorf J; Verhamme P; Bauersachs RM; Prandoni P;
Thromb Haemost; 2016 Sep; 116(4):733-8. PubMed ID: 27583311
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban Versus Warfarin and Risk of Post-Thrombotic Syndrome Among Patients with Venous Thromboembolism.
Søgaard M; Nielsen PB; Skjøth F; Kjældgaard JN; Coleman CI; Larsen TB
Am J Med; 2018 Jul; 131(7):787-794.e4. PubMed ID: 29476744
[TBL] [Abstract][Full Text] [Related]
7. Resolution of acute lower extremity deep vein thrombosis with rivaroxaban compared to warfarin.
Houghton DE; Lekah A; Macedo TA; Hodge D; Saadiq RA; Little Y; Casanegra AI; McBane RD; Wysokinski WE
J Thromb Thrombolysis; 2020 Feb; 49(2):199-205. PubMed ID: 31422520
[TBL] [Abstract][Full Text] [Related]
8. Comparing Safety and Efficacy of Rivaroxaban with Warfarin for Patients after Successful Stent Placement for Chronic Iliofemoral Occlusion: A Retrospective Single Institution Study.
Zhang X; Huang J; Peng Z; Lu X; Yang X; Ye K
Eur J Vasc Endovasc Surg; 2021 Mar; 61(3):484-489. PubMed ID: 33388238
[TBL] [Abstract][Full Text] [Related]
9. Use of Micronized Purified Flavonoid Fraction Together with Rivaroxaban Improves Clinical and Ultrasound Outcomes in Femoropopliteal Venous Thrombosis: Results of a Pilot Clinical Trial.
Lobastov K; Schastlivtsev I; Barinov V
Adv Ther; 2019 Jan; 36(1):72-85. PubMed ID: 30539384
[TBL] [Abstract][Full Text] [Related]
10. Treatment of deep vein thrombosis with rivaroxaban and its potential to prevent the post-thrombotic syndrome.
Antignani PL; Allegra C; Fareed J
Int Angiol; 2019 Feb; 38(1):17-21. PubMed ID: 30465419
[TBL] [Abstract][Full Text] [Related]
11. Risk of post-thrombotic syndrome after deep vein thrombosis treated with rivaroxaban versus vitamin-K antagonists: A systematic review and meta-analysis.
Li R; Yuan M; Cheng J; Yu S; Wei W; Fu W; Prandoni P; Chen Y
Thromb Res; 2020 Dec; 196():340-348. PubMed ID: 32977134
[TBL] [Abstract][Full Text] [Related]
12. The risk of post-thrombotic syndrome in patients with proximal deep vein thrombosis treated with the direct oral anticoagulants.
Prandoni P; Ageno W; Ciammaichella M; Mumoli N; Zanatta N; Imberti D; Visonà A; Bucherini E; Di Nisio M; Noventa F;
Intern Emerg Med; 2020 Apr; 15(3):447-452. PubMed ID: 31667697
[TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban or vitamin-K antagonists following early endovascular thrombus removal and stent placement for acute iliofemoral deep vein thrombosis.
Sebastian T; Hakki LO; Spirk D; Baumann FA; Périard D; Banyai M; Spescha RS; Kucher N; Engelberger RP
Thromb Res; 2018 Dec; 172():86-93. PubMed ID: 30391776
[TBL] [Abstract][Full Text] [Related]
14. Patterns and Predictors of Use of Anticoagulants for the Treatment of Venous Thromboembolism Following Approval of Rivaroxaban.
Dault R; Vanasse A; Blais L; Perreault S; Farand P; Le Templier G; Beauchesne MF
Clin Appl Thromb Hemost; 2016 Nov; 22(8):765-771. PubMed ID: 26467323
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state.
Coleman CI; Turpie AGG; Bunz TJ; Baker WL; Beyer-Westendorf J
Thromb Res; 2018 Mar; 163():132-137. PubMed ID: 29407625
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
[TBL] [Abstract][Full Text] [Related]
17. Guidance for the prevention and treatment of the post-thrombotic syndrome.
Kahn SR; Galanaud JP; Vedantham S; Ginsberg JS
J Thromb Thrombolysis; 2016 Jan; 41(1):144-53. PubMed ID: 26780743
[TBL] [Abstract][Full Text] [Related]
18. Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long-term cross-sectional follow-up of RE-COVER study patients.
Wik HS; Kahn SR; Eriksson H; Morrison D; Ghanima W; Schulman S; Sandset PM
J Thromb Haemost; 2021 Oct; 19(10):2495-2503. PubMed ID: 34255420
[TBL] [Abstract][Full Text] [Related]
19. Low incidence of post-thrombotic syndrome in patients treated with new oral anticoagulants and percutaneous endovenous intervention for lower extremity deep venous thrombosis.
Sharifi M; Freeman W; Bay C; Sharifi M; Schwartz F
Vasc Med; 2015 Apr; 20(2):112-6. PubMed ID: 25832599
[TBL] [Abstract][Full Text] [Related]
20. Costs of hospital visits among patients with deep vein thrombosis treated with rivaroxaban and LMWH/warfarin.
Merli GJ; Hollander JE; Lefebvre P; Laliberté F; Raut MK; Germain G; Bookhart B; Pollack CV
J Med Econ; 2016; 19(1):84-90. PubMed ID: 26390315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
